ClinicalTrials.gg
CompletedNCT03611556Updated Oct 3, 2023Results posted

MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

A Phase 1/2 interventional study of Oleclumab and Durvalumab in Carcinoma and Metastatic Pancreatic Adenocarcinoma, sponsored by MedImmune LLC. Completed at 27 sites in 4 countries. Open to participants aged 18 Years to 101 Years. Per ClinicalTrials.gov, last updated 2023-10-03.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
213
Allocation
Randomized
Ages
18 Years to 101 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing gemcitabine in Carcinoma — 1 open to participants now, 3 under way, 1 of them phase 3. Gemcitabine · Carcinoma.

Enrollment
2nd of 16
213 · median 44
Started
2018
the only one that year
Phase 1/2
2 of 16
none open now
Registered
15th of 16
by date
Lead sponsor
1 of 16
MedImmune LLC

Among the 16 studies testing gemcitabine in Carcinoma, this one is the 2nd largest by enrollment, is the only one that started in 2018, is one of 2 in phase 1/2, and was the 15th registered.

Carcinoma

736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.

Browse Carcinoma studies →

Open to participants now

1 of the 16 studies testing gemcitabine in Carcinoma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 101 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing gemcitabine in Carcinoma, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the safety, tolerability, and antitumor activity of oleclumab (MEDI9447) in combination with or without durvalumab plus chemotherapy in participants with metastatic pancreatic cancer.

Read the detailed description

This is a Phase 1b/2, multicenter, open-label, dose-escalation, and dose-expansion study to assess the safety, preliminary antitumor activity, immunogenicity, and pharmacokinetics (PK) of oleclumab with or without durvalumab in combination with chemotherapy administered in participants with metastatic pancreatic ductal adenocarcinoma (PDAC). Participants with previously untreated metastatic PDAC (first-line [1L] metastatic PDAC) will be enrolled in Cohort A. Participants with metastatic PDAC previously treated with gemcitabine-based chemotherapy (without exposure to 5-fluorouracil [5-FU], capecitabine, or oxaliplatin; second-line [2L] metastatic PDAC) will be enrolled in Cohort B. The study consists of 2 parts, dose escalation (Part 1) and dose expansion (Part 2).

03

Conditions studied

  • Carcinoma
  • Metastatic Pancreatic Adenocarcinoma

Keywords

  • MEDI9447
  • oleclumab
  • immunotherapy
  • pancreatic cancer
  • durvalumab
04

Who can participate

Ages eligible
18 Years to 101 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >= 18
  2. Written and signed must be obtained
  3. (ECOG) Performance Status 0 or 1
  4. Weight >= 35 kg
  5. Participants must have histologically or cytologically, confirmed pancreatic adenocarcinoma:

    Cohort A: Participants with previously untreated pancreatic adenocarcinoma (1L metastatic disease) not previously treated with systemic therapies Cohort B: Participants with metastatic pancreatic adenocarcinoma previously treated with gemcitabine-based chemotherapy (without exposure to 5-FU, capecitabine, oxaliplatin) 2L metastatic disease

  6. Participants must have at least 1 according to v1.1
  7. All Participants must consent to providing .

Exclusion criteria

Exclusion Criteria:

  1. Receipt of any conventional or anticancer therapy within 21 days or palliative radiotherapy within 14 days prior to the scheduled first dose of study treatment.
  2. Prior receipt of any immune-related therapy
  3. Concurrent enrollment in another therapeutic clinical study. Enrollment in observational studies will be allowed.
  4. Participants with a history of venous thrombosis within the past 3 months
  5. Participants with prior history of myocardial infarction, , or stroke in the last 3 months prior to start of treatment
  6. Active or prior documented or inflammatory disorders within the past 3 years prior to the start of treatment
  7. Other invasive within 2 years
  8. Any history of or cord compression
  9. Current or prior use of medication within 14 days prior to the first dose.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
213 participants (actual)

Study arms

  • Experimental
    Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + nab-paclitaxel

    Participants with 1L metastatic disease will receive intravenous (IV) infusions of oleclumab 1500 mg every 2 weeks for 4 doses, then every 4 weeks (Q4W) in combination with durvalumab 1500 mg Q4W plus chemotherapy of gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2, both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion is met.

    Drug: Oleclumab · Drug: Durvalumab · Drug: Gemcitabine · Drug: Nab-paclitaxel

  • Experimental
    Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + nab-paclitaxel

    Participants with 1L metastatic disease will receive IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with durvalumab 1500 mg Q4W plus chemotherapy of gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2, both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion is met.

    Drug: Oleclumab · Drug: Durvalumab · Drug: Gemcitabine · Drug: Nab-paclitaxel

  • Experimental
    Dose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOX

    Participants with 2L metastatic disease will receive IV infusions of oleclumab 1500 mg every 2 weeks for 4 doses, then Q4W in combination with durvalumab 1500 mg Q4W plus chemotherapy of mFOLFOX (oxaliplatin 85 mg/m\^2 IV; folinic acid 400 mg/m\^2 IV; 5-FU 400 mg/m\^2 IV bolus followed by 2400 mg/m\^2 continuous IV infusion over 46 to 48 hours) on Days 1 and 15 and then repeated on a Q4W schedule, until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion is met.

    Drug: Oleclumab · Drug: Durvalumab · Drug: Oxaliplatin · Drug: Folinic acid · Drug: 5-FU

  • Experimental
    Dose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX

    Participants with 2L metastatic disease will receive IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with durvalumab 1500 mg Q4W plus chemotherapy of mFOLFOX (oxaliplatin 85 mg/m\^2 IV; folinic acid 400 mg/m\^2 IV; 5-FU 400 mg/m\^2 IV bolus followed by 2400 mg/m\^2 continuous IV infusion over 46 to 48 hours) on Days 1 and 15 and then repeated on a Q4W schedule, until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion is met.

    Drug: Oleclumab · Drug: Durvalumab · Drug: Oxaliplatin · Drug: Folinic acid · Drug: 5-FU

  • Active comparator
    Dose-expansion, Gemcitabine + nab-paclitaxel

    Participants with 1L metastatic disease will receive IV infusions of chemotherapy of gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2, both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion is met.

    Drug: Gemcitabine · Drug: Nab-paclitaxel

  • Experimental
    Dose-expansion, Oleclumab 3000 mg + Gemcitabine + nab-paclitaxel

    Participants with 1L metastatic disease will receive IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with chemotherapy of gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2, both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion is met.

    Drug: Oleclumab · Drug: Gemcitabine · Drug: Nab-paclitaxel

  • Experimental
    Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + nab-paclitaxel

    Participants with 1L metastatic disease will receive IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with durvalumab 1500 mg Q4W plus chemotherapy of gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2, both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion is met.

    Drug: Oleclumab · Drug: Durvalumab · Drug: Gemcitabine · Drug: Nab-paclitaxel

Interventions

  • Participants will receive IV infusion of oleclumab as stated in arm description.

    Also known as: MEDI9447

  • Participants will receive IV infusion of durvalumab as stated in arm description.

    Also known as: MEDI4736

  • Participants will receive IV infusion of gemcitabine as stated in arm description.

  • Participants will receive IV infusion of nab-paclitaxel as stated in arm description.

  • Participants will receive IV infusion of oxaliplatin as stated in arm description.

    Also known as: Modified FOLFOX (oxaliplatin, folinic acid, and 5-FU)

  • Participants will receive IV infusion of folinic acid as stated in arm description.

    Also known as: Modified FOLFOX (oxaliplatin, folinic acid, and 5-FU)

  • Drug5-FU

    Participants will receive IV infusion of 5-FU as stated in arm description.

    Also known as: Modified FOLFOX (oxaliplatin, folinic acid, and 5-FU)

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) in Dose Escalation Phase

    An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.

    Time frame: Day 1 through 65.7 weeks (maximum observed duration)

  2. Number of Participants With Dose-limiting Toxicities (DLTs) in Dose Escalation Phase

    DLT: Any study drug related Grade (G)3 or higher toxicity including: any G4 immune-mediated AEs, \>=G3 colitis/pneumonitis/interstitial lung disease (ILD), \>=G3 nausea/vomiting/diarrhea that does not resolve to G2 or less within 3 days of maximal supportive care (MSC), G2 pneumonitis/ILD that does not resolve within 7 days of initiation of MSC, G4 anemia, G3 anemia with clinical sequelae/requires \>2 units of red blood cells transfusion, G4 thrombocytopenia/neutropenia \>=7 days, G3/4 thrombocytopenia with \>=G3 hemorrhage, G4 febrile neutropenia (FN), G3 FN lasting \>=5 days while receiving MSC, isolated G3 liver transaminase elevation (LTE)/ isolated G3 total bilirubin (TBL) that does not downgrade to G1 or less within 14 days of onset, isolated G4 LTE or TBL, elevated aspartate aminotransferase/alanine aminotransferase \>3×upper limit of normal (ULN) and concurrent TBL \>2×ULN without cholestasis or alternative explanations, any other toxicity judged as a DLT by Dose Escalation Committee.

    Time frame: From Day 1 to 28 days after the first dose of study drugs

  3. Number of Participants With Abnormal Vital Signs Reported as TEAEs in Dose Escalation Phase

    Number of participants with abnormal vital signs (temperature, blood pressure, pulse rate, and respiratory rate) reported as TEAEs are reported.

    Time frame: Day 1 through 65.7 weeks (maximum observed duration)

  4. Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs in Dose Escalation Phase

    Number of participants with abnormal ECG parameters reported as TEAEs are reported.

    Time frame: Day 1 through 65.7 weeks (maximum observed duration)

  5. Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs in Dose Escalation Phase

    Number of participants with abnormal clinical laboratory parameters reported as TEAEs are reported.

    Time frame: Day 1 through 65.7 weeks (maximum observed duration)

  6. Percentage of Participants With Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Dose Expansion Phase

    The OR is defined as best overall response of confirmed complete response (CR) or confirmed partial response (PR) based on RECIST v1.1 guidelines. The CR is defined as disappearance of all target lesions (TLs) and non-target lesions (NTLs), any pathological lymph nodes (target and non-target) must have reduction in short axis \< 10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the sum of the diameters (SoD) of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. Percentage of participants with OR is reported.

    Time frame: Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)

Secondary outcomes

  1. Number of Participants With TEAEs and TESAEs in Dose Expansion Phase

    An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.

    Time frame: Day 1 through 172.1 weeks (maximum observed duration)

  2. Number of Participants With Abnormal Vital Signs Reported as TEAEs in Dose Expansion Phase

    Number of participants with abnormal vital signs (temperature, blood pressure, pulse rate, and respiratory rate) reported as TEAEs are reported.

    Time frame: Day 1 through 172.1 weeks (maximum observed duration)

  3. Number of Participants With Abnormal ECG Parameters Reported as TEAEs in Dose Expansion Phase

    Number of participants with abnormal ECG parameters reported as TEAEs are reported.

    Time frame: Day 1 through 172.1 weeks (maximum observed duration)

  4. Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs in Dose Expansion Phase

    Number of participants with abnormal clinical laboratory parameters reported as TEAEs are reported.

    Time frame: Day 1 through 172.1 weeks (maximum observed duration)

  5. Percentage of Participants With OR According to RECIST v1.1 in Dose Escalation Phase

    The OR is defined as best overall response of confirmed CR or confirmed PR based on RECIST v1.1 guidelines. The CR is defined as disappearance of all target and non-target lesions, any pathological lymph nodes (target and non-target) must have reduction in short axis \< 10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the sum of the diameters of target lesions (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. Percentage of participants with OR is reported.

    Time frame: Baseline (Days -28 to -1) through 24.5 months (maximum observed duration)

  6. Percentage of Participants With Disease Control (DC) According to RECIST v1.1 in Dose Escalation Phase

    The DC is defined as confirmed CR, PR, or stable disease (SD) (maintained for \>=8 weeks). The CR is defined as disappearance of all TLs and NTLs, any pathological lymph nodes (target and non-target) must have reduction in short axis \<10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the SoD of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from date of first documentation. The SD is defined as neither sufficient shrinkage of TLs to qualify for PR nor sufficient increase of TLs to qualify for progressive disease (PD), taking as reference the smallest SoD while on study, and no new lesions. The PD is defined as at least a 20% increase in SoD of TLs, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of SoD, or unequivocal progression of existing NTLs, or the appearance of new lesion/s. Percentage of participants with DC is reported.

    Time frame: Baseline (Days -28 to -1) through 24.5 months (maximum observed duration)

  7. Number of Participants With Overall Survival Events in Dose Expansion Phase

    The overall survival is defined as the time from the randomization until death due to any cause. For participants who were alive at the time of data cut off, overall survival was censored on the last date when participants were known to be alive. The overall survival is assessed using the Kaplan-Meier method. The number of participants with overall survival events (deaths) is reported.

    Time frame: Baseline (Days -28 to -1) through 38.7 months (maximum observed duration)

  8. Overall Survival in Dose Expansion Phase

    The overall survival is defined as the time from the randomization until death due to any cause. For participants who were alive at the time of data cut off, overall survival was censored on the last date when participants were known to be alive. The overall survival is assessed using the Kaplan-Meier method.

    Time frame: Baseline (Days -28 to -1) through 38.7 months (maximum observed duration)

  9. Number of Participants With Progression-free Survival Events According to RECIST v1.1 in Dose Expansion Phase

    Progression-free survival (PFS) is defined as the time from randomization until the first documentation of a PD or death due to any cause, whichever occurred first, regardless of whether the participant received subsequent anticancer treatment prior to progression. The PD is defined as at least a 20% increase in sum of the diameters of target lesions, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of sum of the diameters, or unequivocal progression of existing non-target lesions, or the appearance of new lesion/s. Participants who had no documented progression and were still alive at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST v1.1 assessment. The PFS is assessed using the Kaplan-Meier method. The number of participants with PFS events is reported.

    Time frame: Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)

  10. Progression-free Survival According to RECIST v1.1 in Dose Expansion Phase

    The PFS is defined as the time from randomization until the first documentation of a PD or death due to any cause, whichever occurred first, regardless of whether the participant received subsequent anticancer treatment prior to progression. The PD is defined as at least a 20% increase in sum of the diameters of target lesions, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of sum of the diameters, or unequivocal progression of existing non-target lesions, or the appearance of new lesion/s. Participants who had no documented progression and were still alive at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST v1.1 assessment. The PFS is assessed using the Kaplan-Meier method.

    Time frame: Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)

  11. Duration of Response (DoR) According to RECIST v1.1 in Dose Expansion Phase

    The DoR is defined as the time from the first documentation of an OR until the first documentation of a PD or death due to any cause, whichever occurs first. The OR is defined as best overall response of confirmed CR or PR based on RECIST v1.1 guidelines. The CR is defined as disappearance of all TLs and NTLs, any pathological lymph nodes (target and non-target) must have reduction in short axis \< 10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the SoD of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. The PD is defined as at least a 20% increase in SoD of TLs, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of SoD, or unequivocal progression of existing NTLs, or the appearance of new lesion/s. The DoR is assessed using the Kaplan-Meier method.

    Time frame: Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)

  12. Percentage of Participants With DC According to RECIST v1.1 in Dose Expansion Phase

    The DC is defined as confirmed CR, PR, or stable disease (SD) (maintained for \>=8 weeks). The CR is defined as disappearance of all TLs and NTLs, any pathological lymph nodes (target and non-target) must have reduction in short axis \<10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the SoD of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from date of first documentation. The SD is defined as neither sufficient shrinkage of TLs to qualify for PR nor sufficient increase of TLs to qualify for PD, taking as reference the smallest SoD while on study, and no new lesions. The PD is defined as at least a 20% increase in SoD of TLs, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of SoD, or unequivocal progression of existing NTLs, or the appearance of new lesion/s. Percentage of participants with DC is reported.

    Time frame: Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)

  13. Percentage of Participants With OR According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase

    The OR is defined as best overall response of confirmed CR or confirmed PR based on RECIST v1.1. The CR is defined as disappearance of all TLs and NTLs, any pathological lymph nodes (target and non-target) must have reduction in short axis \<10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the SoD of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. The OR is assessed by cluster of differentiation 73 (CD73) expression level either low or high at baseline. The CD73 low is defined as no CD73 expression in tumor cells or \<50% of tumor cells with 2+ or 3+ intensity and CD73 high is defined as CD73 expression with 2+ or 3+ intensity in \>=50% of tumor cells.

    Time frame: Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)

  14. Number of Participants With Overall Survival Events by CD73 Expression at Baseline in Dose Expansion Phase

    The overall survival is defined as the time from the randomization until death due to any cause. For participants who were alive at the time of data cut off, overall survival was censored on the last date when participants were known to be alive. The overall survival is assessed by CD73 expression level either low or high at baseline using the Kaplan-Meier method. The CD73 low is defined as no CD73 expression in tumor cells or \<50% of tumor cells with 2+ or 3+ intensity and CD73 high is defined as CD73 expression with 2+ or 3+ intensity in \>=50% of tumor cells. The number of participants with overall survival events (deaths) is reported.

    Time frame: Baseline (Days -28 to -1) through 38.7 months (maximum observed duration)

  15. Overall Survival by CD73 Expression at Baseline in Dose Expansion Phase

    The overall survival is defined as the time from the randomization until death due to any cause. For participants who were alive at the time of data cut off, overall survival was censored on the last date when participants were known to be alive. The overall survival is assessed by CD73 expression level either low or high at baseline using the Kaplan-Meier method. The CD73 low is defined as no CD73 expression in tumor cells or \<50% of tumor cells with 2+ or 3+ intensity and CD73 high is defined as CD73 expression with 2+ or 3+ intensity in \>=50% of tumor cells.

    Time frame: Baseline (Days -28 to -1) through 38.7 months (maximum observed duration)

  16. Number of Participants With Progression-free Survival Events According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase

    PFS: Time from randomization until first documentation of PD/death due to any cause, whichever occurred first, regardless of whether participant received subsequent anticancer treatment prior to progression. PD:\>=20% increase in SoD of TLs and an absolute increase of \>= 5 mm of SoD/unequivocal progression of existing NTLs/appearance of new lesion. Participants who had no documented progression and were still alive at the time of analysis were censored at time of latest date of assessment from their last evaluable RECIST v1.1 assessment. PFS is assessed by CD73 expression level either low/high at baseline using Kaplan-Meier method. CD73 low: No CD73 expression in tumor cells/\<50% of tumor cells with 2+/3+ intensity. CD73 high: CD73 expression with 2+/3+ intensity in \>=50% of tumor cells. Number of participants with PFS events is reported.

    Time frame: Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)

  17. Progression-free Survival According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase

    The PFS is defined as the time from randomization until the first documentation of a PD or death due to any cause, whichever occurred first, regardless of whether the participant receives subsequent anticancer treatment prior to progression. The PD is defined as at least a 20% increase in SoD of TLs, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of SoD, or unequivocal progression of existing NTLs, or the appearance of new lesion/s. Participants who had no documented progression and were still alive at time of analysis were censored at time of latest date of assessment from their last evaluable RECIST v1.1 assessment. PFS is assessed by CD73 expression level either low/high at baseline using Kaplan-Meier method. CD73 low: No CD73 expression in tumor cells/\<50% of tumor cells with 2+/3+ intensity. CD73 high: CD73 expression with 2+/3+ intensity in \>=50% of tumor cells.

    Time frame: Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)

  18. Number of Participants With Positive Anti-drug Antibodies (ADA) to Oleclumab

    Number of participants with positive ADA to oleclumab are reported. Persistent positive is defined as positive at \>= 2 post-baseline assessments (with \>=16 weeks between first and last positive) or positive at last post-baseline assessment. Transient positive is defined as negative at last post-baseline assessment and positive at only one post-baseline assessment or at \>= 2 post-baseline assessments (with \<16 weeks between first and last positive). Treatment-boosted ADA is defined as baseline ADA positive titer that was boosted to a 4-fold or higher level following drug administration.

    Time frame: Day 1 through 172.1 weeks (Pre-dose on Cycle [C] 1 Day [D] 1, C2D1, C3D1, Day 1 of every 3 cycles starting with C5, through 12 weeks post last dose of oleclumab)

  19. Number of Participants With Positive ADA to Durvalumab

    Number of participants with positive ADA to durvalumab are reported. Persistent positive is defined as positive at \>= 2 post-baseline assessments (with \>=16 weeks between first and last positive) or positive at last post-baseline assessment. Transient positive is defined as negative at last post-baseline assessment and positive at only one post-baseline assessment or at \>= 2 post-baseline assessments (with \<16 weeks between first and last positive). Treatment-boosted ADA is defined as baseline ADA positive titer that was boosted to a 4-fold or higher level following drug administration.

    Time frame: Day 1 through 128 weeks (Pre-dose on C1D1, C2D1, C3D1, Day 1 of every 3 cycles starting with C5, through 12 weeks post last dose of durvalumab)

  20. Serum Concentrations of Oleclumab

    Serum concentrations of oleclumab are reported.

    Time frame: Ten minutes (mins) (± 5 mins) post end of infusion (EOI), approximately 1 hour (+ 15 mins) after start of infusion on C1D1, C3D1, and C5D1; and pre-dose on C3D1 and C5D1

  21. Serum Concentrations of Durvalumab

    Serum concentrations of durvalumab are reported.

    Time frame: Ten mins (± 5 mins) post EOI, approximately 1 hour (+ 15 mins) after start of infusion on C1D1 and C5D1; and pre-dose on C2D1 and C5D1

  22. Plasma Concentrations of Gemcitabine and Metabolite 2',2'-Difluorodeoxyuridine (dFdU)

    Plasma concentrations of gemcitabine and metabolite dFdU are reported.

    Time frame: Ten mins (± 5 mins) post EOI, approximately 30-40 mins after start of infusion on C1D1 and C4D1; and pre-dose on C4D1

  23. Plasma Concentrations of Nab-paclitaxel

    Plasma concentrations of nab-paclitaxel are reported.

    Time frame: Ten mins (± 5 mins) post EOI, approximately 30-40 mins after start of infusion on C1D1 and C4D1; and pre-dose on C4D1

07

Results

Posted Oct 3, 2023
Limitations and caveats
Dose escalation phase: Participants not enrolled in oleclumab 750 mg cohort. Dose expansion phase: Outcomes of mFOLFOX cohorts not included as enrollment was not opened. Non-compartmental PK data analysis were planned to be performed from each dose cohort if data allowed, but as sparse PK samples were collected, no non-compartmental PK parameters were calculated. Consequently, PK concentration time data only have been reported.

Participant flow

Participant flow — Overall Study
MilestoneDose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOXDose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOXDose-expansion, Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel
Started7738623870
Completed0000000
Not completed7738623870
Withdrew: Death7738473253
Withdrew: Withdrawal by subject0000424
Withdrew: Sponsor decision00009412
Withdrew: Reasons0000201

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) in Dose Escalation Phase

An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.

Time frame:
Day 1 through 65.7 weeks (maximum observed duration)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) in Dose Escalation Phase
ParticipantsDose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOXDose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX
Any TEAEs7738
Any TESAEs4604
PrimaryNumber of Participants With Dose-limiting Toxicities (DLTs) in Dose Escalation Phase

DLT: Any study drug related Grade (G)3 or higher toxicity including: any G4 immune-mediated AEs, \>=G3 colitis/pneumonitis/interstitial lung disease (ILD), \>=G3 nausea/vomiting/diarrhea that does not resolve to G2 or less within 3 days of maximal supportive care (MSC), G2 pneumonitis/ILD that does not resolve within 7 days of initiation of MSC, G4 anemia, G3 anemia with clinical sequelae/requires \>2 units of red blood cells transfusion, G4 thrombocytopenia/neutropenia \>=7 days, G3/4 thrombocytopenia with \>=G3 hemorrhage, G4 febrile neutropenia (FN), G3 FN lasting \>=5 days while receiving MSC, isolated G3 liver transaminase elevation (LTE)/ isolated G3 total bilirubin (TBL) that does not downgrade to G1 or less within 14 days of onset, isolated G4 LTE or TBL, elevated aspartate aminotransferase/alanine aminotransferase \>3×upper limit of normal (ULN) and concurrent TBL \>2×ULN without cholestasis or alternative explanations, any other toxicity judged as a DLT by Dose Escalation Committee.

Time frame:
From Day 1 to 28 days after the first dose of study drugs
Reported as:
Count of participants · Participants
Number of Participants With Dose-limiting Toxicities (DLTs) in Dose Escalation Phase
ParticipantsDose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOXDose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX
Number of Participants With Dose-limiting Toxicities (DLTs) in Dose Escalation Phase0001
PrimaryNumber of Participants With Abnormal Vital Signs Reported as TEAEs in Dose Escalation Phase

Number of participants with abnormal vital signs (temperature, blood pressure, pulse rate, and respiratory rate) reported as TEAEs are reported.

Time frame:
Day 1 through 65.7 weeks (maximum observed duration)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Vital Signs Reported as TEAEs in Dose Escalation Phase
ParticipantsDose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOXDose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX
Pyrexia3301
Dyspnoea1000
Dyspnoea exertional0100
Hypotension2101
Temperature intolerance0010
Hypertension0001
PrimaryNumber of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs in Dose Escalation Phase

Number of participants with abnormal ECG parameters reported as TEAEs are reported.

Time frame:
Day 1 through 65.7 weeks (maximum observed duration)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs in Dose Escalation Phase
ParticipantsDose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOXDose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX
Atrial fibrillation0100
Tachycardia0100
Atrioventricular block0001
PrimaryNumber of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs in Dose Escalation Phase

Number of participants with abnormal clinical laboratory parameters reported as TEAEs are reported.

Time frame:
Day 1 through 65.7 weeks (maximum observed duration)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs in Dose Escalation Phase
ParticipantsDose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOXDose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX
Anaemia3310
Neutropenia2221
Thrombocytopenia2221
Hypothyroidism0101
Alanine aminotransferase increased3402
Aspartate aminotransferase increased3303
Blood alkaline phosphatase increased2101
Blood bilirubin increased1001
Blood creatinine increased0300
Blood glucose decreased1000
International normalised ratio increased1000
Lymphocyte count decreased0102
Neutrophil count decreased0213
Platelet count decreased1312
White blood cell count decreased0202
Hypoalbuminaemia0201
Hypocalcaemia0101
Hypokalaemia0302
Hypomagnesaemia1201
Hyponatraemia0202
Hypophosphataemia0100
Proteinuria1000
Hyperthyroidism0001
Amylase increased0011
Gamma-glutamyltransferase increased0001
Lipase increased0001
PrimaryPercentage of Participants With Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Dose Expansion Phase

The OR is defined as best overall response of confirmed complete response (CR) or confirmed partial response (PR) based on RECIST v1.1 guidelines. The CR is defined as disappearance of all target lesions (TLs) and non-target lesions (NTLs), any pathological lymph nodes (target and non-target) must have reduction in short axis \< 10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the sum of the diameters (SoD) of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. Percentage of participants with OR is reported.

Time frame:
Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Dose Expansion Phase
Percentage of ParticipantsDose-expansion, Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel
Percentage of Participants With Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Dose Expansion Phase29.0 (18.2 to 41.9)21.1 (9.6 to 37.3)32.9 (22.1 to 45.1)
Statistical analysis
  • Dose-expansion, Gemcitabine + Nab-paclitaxel vs Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel · Cochran-Mantel-Haenszel · p = 0.3614 (Nominal P-value for comparison of treatment groups obtained from Cochran-Mantel-Haenszel-test was stratified by cluster of differentiation 73 (CD73) level.) · Rate difference: -8.0 · 95% CI -27.6 to 12.1
  • Dose-expansion, Gemcitabine + Nab-paclitaxel vs Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel · Cochran-Mantel-Haenszel · p = 0.6503 (Nominal P-value for comparison of treatment groups obtained from Cochran-Mantel-Haenszel-test was stratified by CD73 level.) · Rate difference: 3.8 · 95% CI -13.2 to 20.7
SecondaryNumber of Participants With TEAEs and TESAEs in Dose Expansion Phase

An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.

Time frame:
Day 1 through 172.1 weeks (maximum observed duration)
Reported as:
Count of participants · Participants
Number of Participants With TEAEs and TESAEs in Dose Expansion Phase
ParticipantsDose-expansion, Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel
Any TEAEs623770
Any TESAEs342437
SecondaryNumber of Participants With Abnormal Vital Signs Reported as TEAEs in Dose Expansion Phase

Number of participants with abnormal vital signs (temperature, blood pressure, pulse rate, and respiratory rate) reported as TEAEs are reported.

Time frame:
Day 1 through 172.1 weeks (maximum observed duration)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Vital Signs Reported as TEAEs in Dose Expansion Phase
ParticipantsDose-expansion, Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel
Hypothermia001
Pyrexia151221
Dyspnoea768
Dyspnoea exertional112
Hypertension2311
Hypotension344
Orthostatic hypotension100
SecondaryNumber of Participants With Abnormal ECG Parameters Reported as TEAEs in Dose Expansion Phase

Number of participants with abnormal ECG parameters reported as TEAEs are reported.

Time frame:
Day 1 through 172.1 weeks (maximum observed duration)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal ECG Parameters Reported as TEAEs in Dose Expansion Phase
ParticipantsDose-expansion, Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel
Supraventricular tachycardia010
Tachycardia233
SecondaryNumber of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs in Dose Expansion Phase

Number of participants with abnormal clinical laboratory parameters reported as TEAEs are reported.

Time frame:
Day 1 through 172.1 weeks (maximum observed duration)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs in Dose Expansion Phase
ParticipantsDose-expansion, Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel
Anaemia171428
Febrile neutropenia013
Leukocytosis101
Leukopenia123
Lymphopenia202
Neutropenia221516
Thrombocytopenia6713
Thrombocytosis201
Hyperthyroidism003
Hypothyroidism007
Hypertransaminasaemia010
Alanine aminotransferase decreased100
Alanine aminotransferase increased8916
Amylase increased101
Aspartate aminotransferase increased11815
Blood albumin decreased100
Blood alkaline phosphatase increased328
Blood bilirubin increased332
Blood creatinine increased208
Blood glucose increased020
Blood lactate dehydrogenase increased103
Blood magnesium decreased010
Blood oestrogen decreased010
Gamma-glutamyltransferase increased618
Haemoglobin decreased001
International normalised ratio increased001
Lipase increased012
Liver function test increased100
Lymphocyte count decreased426
Neutrophil count001
Neutrophil count decreased19824
Platelet count decreased13920
Troponin I increased100
White blood cell count decreased6610
White blood cell count increased010
Hyperglycaemia426
Hyperkalaemia111
Hypoalbuminaemia326
Hypocalcaemia223
Hypoglycaemia002
Hypokalaemia428
Hypomagnesaemia436
Hyponatraemia803
Hypophosphataemia100
Hypovolaemia100
Iron deficiency001
Type 2 diabetes mellitus010
Proteinuria011
SecondaryPercentage of Participants With OR According to RECIST v1.1 in Dose Escalation Phase

The OR is defined as best overall response of confirmed CR or confirmed PR based on RECIST v1.1 guidelines. The CR is defined as disappearance of all target and non-target lesions, any pathological lymph nodes (target and non-target) must have reduction in short axis \< 10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the sum of the diameters of target lesions (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. Percentage of participants with OR is reported.

Time frame:
Baseline (Days -28 to -1) through 24.5 months (maximum observed duration)
Reported as:
Number · Percentage of Participants
Percentage of Participants With OR According to RECIST v1.1 in Dose Escalation Phase
Percentage of ParticipantsDose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOXDose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX
Percentage of Participants With OR According to RECIST v1.1 in Dose Escalation Phase0 (NA to NA)14.3 (0.4 to 57.9)0 (NA to NA)12.5 (0.3 to 52.7)
SecondaryPercentage of Participants With Disease Control (DC) According to RECIST v1.1 in Dose Escalation Phase

The DC is defined as confirmed CR, PR, or stable disease (SD) (maintained for \>=8 weeks). The CR is defined as disappearance of all TLs and NTLs, any pathological lymph nodes (target and non-target) must have reduction in short axis \<10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the SoD of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from date of first documentation. The SD is defined as neither sufficient shrinkage of TLs to qualify for PR nor sufficient increase of TLs to qualify for progressive disease (PD), taking as reference the smallest SoD while on study, and no new lesions. The PD is defined as at least a 20% increase in SoD of TLs, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of SoD, or unequivocal progression of existing NTLs, or the appearance of new lesion/s. Percentage of participants with DC is reported.

Time frame:
Baseline (Days -28 to -1) through 24.5 months (maximum observed duration)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Disease Control (DC) According to RECIST v1.1 in Dose Escalation Phase
Percentage of ParticipantsDose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOXDose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX
Percentage of Participants With Disease Control (DC) According to RECIST v1.1 in Dose Escalation Phase42.9 (9.9 to 81.6)71.4 (29.0 to 96.3)66.7 (9.4 to 99.2)62.5 (24.5 to 91.5)
SecondaryNumber of Participants With Overall Survival Events in Dose Expansion Phase

The overall survival is defined as the time from the randomization until death due to any cause. For participants who were alive at the time of data cut off, overall survival was censored on the last date when participants were known to be alive. The overall survival is assessed using the Kaplan-Meier method. The number of participants with overall survival events (deaths) is reported.

Time frame:
Baseline (Days -28 to -1) through 38.7 months (maximum observed duration)
Reported as:
Number · Participants with event
Number of Participants With Overall Survival Events in Dose Expansion Phase
Participants with eventDose-expansion, Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel
Number of Participants With Overall Survival Events in Dose Expansion Phase473253
Statistical analysis
  • Dose-expansion, Gemcitabine + Nab-paclitaxel vs Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel · Hazard ratio (hr): 1.260 · 95% CI 0.790 to 1.983Hazard ratio for comparison between treatment groups obtained from Cox Proportional Hazards model stratified by CD73 level with ties handled by the Efron method.
  • Dose-expansion, Gemcitabine + Nab-paclitaxel vs Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel · Hazard ratio (hr): 0.750 · 95% CI 0.498 to 1.131Hazard ratio for comparison between treatment groups obtained from Cox Proportional Hazards model stratified by CD73 level with ties handled by the Efron method.
SecondaryOverall Survival in Dose Expansion Phase

The overall survival is defined as the time from the randomization until death due to any cause. For participants who were alive at the time of data cut off, overall survival was censored on the last date when participants were known to be alive. The overall survival is assessed using the Kaplan-Meier method.

Time frame:
Baseline (Days -28 to -1) through 38.7 months (maximum observed duration)
Reported as:
Median · Months
Overall Survival in Dose Expansion Phase
MonthsDose-expansion, Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel
Overall Survival in Dose Expansion Phase10.8 (8.2 to 13.2)8.9 (6.9 to 11.5)12.9 (10.1 to 15.3)
SecondaryNumber of Participants With Progression-free Survival Events According to RECIST v1.1 in Dose Expansion Phase

Progression-free survival (PFS) is defined as the time from randomization until the first documentation of a PD or death due to any cause, whichever occurred first, regardless of whether the participant received subsequent anticancer treatment prior to progression. The PD is defined as at least a 20% increase in sum of the diameters of target lesions, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of sum of the diameters, or unequivocal progression of existing non-target lesions, or the appearance of new lesion/s. Participants who had no documented progression and were still alive at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST v1.1 assessment. The PFS is assessed using the Kaplan-Meier method. The number of participants with PFS events is reported.

Time frame:
Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)
Reported as:
Number · Participants with event
Number of Participants With Progression-free Survival Events According to RECIST v1.1 in Dose Expansion Phase
Participants with eventDose-expansion, Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel
Number of Participants With Progression-free Survival Events According to RECIST v1.1 in Dose Expansion Phase433251
Statistical analysis
  • Dose-expansion, Gemcitabine + Nab-paclitaxel vs Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel · Hazard ratio (hr): 1.160 · 95% CI 0.726 to 1.837Hazard ratio for comparison between treatment groups obtained from Cox Proportional Hazards model stratified by CD73 level with ties handled by the Efron method.
  • Dose-expansion, Gemcitabine + Nab-paclitaxel vs Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel · Hazard ratio (hr): 0.719 · 95% CI 0.468 to 1.105Hazard ratio for comparison between treatment groups obtained from Cox Proportional Hazards model stratified by CD73 level with ties handled by the Efron method.
SecondaryProgression-free Survival According to RECIST v1.1 in Dose Expansion Phase

The PFS is defined as the time from randomization until the first documentation of a PD or death due to any cause, whichever occurred first, regardless of whether the participant received subsequent anticancer treatment prior to progression. The PD is defined as at least a 20% increase in sum of the diameters of target lesions, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of sum of the diameters, or unequivocal progression of existing non-target lesions, or the appearance of new lesion/s. Participants who had no documented progression and were still alive at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST v1.1 assessment. The PFS is assessed using the Kaplan-Meier method.

Time frame:
Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)
Reported as:
Median · Months
Progression-free Survival According to RECIST v1.1 in Dose Expansion Phase
MonthsDose-expansion, Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel
Progression-free Survival According to RECIST v1.1 in Dose Expansion Phase6.7 (5.5 to 9.0)5.6 (3.5 to 7.5)7.5 (5.5 to 10.9)
SecondaryDuration of Response (DoR) According to RECIST v1.1 in Dose Expansion Phase

The DoR is defined as the time from the first documentation of an OR until the first documentation of a PD or death due to any cause, whichever occurs first. The OR is defined as best overall response of confirmed CR or PR based on RECIST v1.1 guidelines. The CR is defined as disappearance of all TLs and NTLs, any pathological lymph nodes (target and non-target) must have reduction in short axis \< 10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the SoD of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. The PD is defined as at least a 20% increase in SoD of TLs, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of SoD, or unequivocal progression of existing NTLs, or the appearance of new lesion/s. The DoR is assessed using the Kaplan-Meier method.

Time frame:
Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)
Reported as:
Median · Months
Duration of Response (DoR) According to RECIST v1.1 in Dose Expansion Phase
MonthsDose-expansion, Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel
Duration of Response (DoR) According to RECIST v1.1 in Dose Expansion Phase7.2 (4.9 to NA)12.9 (2.2 to NA)9.5 (5.7 to 12.0)
SecondaryPercentage of Participants With DC According to RECIST v1.1 in Dose Expansion Phase

The DC is defined as confirmed CR, PR, or stable disease (SD) (maintained for \>=8 weeks). The CR is defined as disappearance of all TLs and NTLs, any pathological lymph nodes (target and non-target) must have reduction in short axis \<10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the SoD of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from date of first documentation. The SD is defined as neither sufficient shrinkage of TLs to qualify for PR nor sufficient increase of TLs to qualify for PD, taking as reference the smallest SoD while on study, and no new lesions. The PD is defined as at least a 20% increase in SoD of TLs, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of SoD, or unequivocal progression of existing NTLs, or the appearance of new lesion/s. Percentage of participants with DC is reported.

Time frame:
Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)
Reported as:
Number · Percentage of Participants
Percentage of Participants With DC According to RECIST v1.1 in Dose Expansion Phase
Percentage of ParticipantsDose-expansion, Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel
Percentage of Participants With DC According to RECIST v1.1 in Dose Expansion Phase66.1 (53.0 to 77.7)73.7 (56.9 to 86.6)75.7 (64.0 to 85.2)
SecondaryPercentage of Participants With OR According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase

The OR is defined as best overall response of confirmed CR or confirmed PR based on RECIST v1.1. The CR is defined as disappearance of all TLs and NTLs, any pathological lymph nodes (target and non-target) must have reduction in short axis \<10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the SoD of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. The OR is assessed by cluster of differentiation 73 (CD73) expression level either low or high at baseline. The CD73 low is defined as no CD73 expression in tumor cells or \<50% of tumor cells with 2+ or 3+ intensity and CD73 high is defined as CD73 expression with 2+ or 3+ intensity in \>=50% of tumor cells.

Time frame:
Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)
Reported as:
Number · Percentage of Participants
Percentage of Participants With OR According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase
Percentage of ParticipantsGemcitabine + Nab-paclitaxel: CD73 Level = HighOleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = HighOleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = HighGemcitabine + Nab-paclitaxel: CD73 Level = LowOleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = LowOleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = Low
Percentage of Participants With OR According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase23.9 (12.6 to 38.8)22.2 (8.6 to 42.3)31.4 (19.1 to 45.9)43.8 (19.8 to 70.1)18.2 (2.3 to 51.8)36.8 (16.3 to 61.6)
Statistical analysis
  • Gemcitabine + Nab-paclitaxel: CD73 Level = High vs Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = High · Rate difference: -1.7 · 95% CI -25.2 to 21.9
  • Gemcitabine + Nab-paclitaxel: CD73 Level = High vs Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = High · Rate difference: 7.5 · 95% CI -12.6 to 27.0
  • Gemcitabine + Nab-paclitaxel: CD73 Level = Low vs Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = Low · Rate difference: -25.6 · 95% CI -58.3 to 13.9
  • Gemcitabine + Nab-paclitaxel: CD73 Level = Low vs Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = Low · Rate difference: -6.9 · 95% CI -39.1 to 26.6
SecondaryNumber of Participants With Overall Survival Events by CD73 Expression at Baseline in Dose Expansion Phase

The overall survival is defined as the time from the randomization until death due to any cause. For participants who were alive at the time of data cut off, overall survival was censored on the last date when participants were known to be alive. The overall survival is assessed by CD73 expression level either low or high at baseline using the Kaplan-Meier method. The CD73 low is defined as no CD73 expression in tumor cells or \<50% of tumor cells with 2+ or 3+ intensity and CD73 high is defined as CD73 expression with 2+ or 3+ intensity in \>=50% of tumor cells. The number of participants with overall survival events (deaths) is reported.

Time frame:
Baseline (Days -28 to -1) through 38.7 months (maximum observed duration)
Reported as:
Number · Participants with event
Number of Participants With Overall Survival Events by CD73 Expression at Baseline in Dose Expansion Phase
Participants with eventGemcitabine + Nab-paclitaxel: CD73 Level = HighOleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = HighOleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = HighGemcitabine + Nab-paclitaxel: CD73 Level = LowOleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = LowOleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = Low
Number of Participants With Overall Survival Events by CD73 Expression at Baseline in Dose Expansion Phase372239101014
Statistical analysis
  • Gemcitabine + Nab-paclitaxel: CD73 Level = High vs Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = High · Hazard ratio (hr): 1.173 · 95% CI 0.676 to 1.985Hazard ratio for comparison between treatment groups obtained from Cox Proportional Hazards model with ties handled by the Efron method.
  • Gemcitabine + Nab-paclitaxel: CD73 Level = High vs Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = High · Hazard ratio (hr): 0.605 · 95% CI 0.377 to 0.968Hazard ratio for comparison between treatment groups obtained from Cox Proportional Hazards model with ties handled by the Efron method.
  • Gemcitabine + Nab-paclitaxel: CD73 Level = Low vs Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = Low · Hazard ratio (hr): 1.549 · 95% CI 0.622 to 3.917Hazard ratio for comparison between treatment groups obtained from Cox Proportional Hazards model with ties handled by the Efron method.
  • Gemcitabine + Nab-paclitaxel: CD73 Level = Low vs Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = Low · Hazard ratio (hr): 1.472 · 95% CI 0.638 to 3.576Hazard ratio for comparison between treatment groups obtained from Cox Proportional Hazards model with ties handled by the Efron method.
SecondaryOverall Survival by CD73 Expression at Baseline in Dose Expansion Phase

The overall survival is defined as the time from the randomization until death due to any cause. For participants who were alive at the time of data cut off, overall survival was censored on the last date when participants were known to be alive. The overall survival is assessed by CD73 expression level either low or high at baseline using the Kaplan-Meier method. The CD73 low is defined as no CD73 expression in tumor cells or \<50% of tumor cells with 2+ or 3+ intensity and CD73 high is defined as CD73 expression with 2+ or 3+ intensity in \>=50% of tumor cells.

Time frame:
Baseline (Days -28 to -1) through 38.7 months (maximum observed duration)
Reported as:
Median · Months
Overall Survival by CD73 Expression at Baseline in Dose Expansion Phase
MonthsGemcitabine + Nab-paclitaxel: CD73 Level = HighOleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = HighOleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = HighGemcitabine + Nab-paclitaxel: CD73 Level = LowOleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = LowOleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = Low
Overall Survival by CD73 Expression at Baseline in Dose Expansion Phase9.9 (6.8 to 12.2)7.9 (4.2 to 9.7)12.1 (8.6 to 15.0)22.2 (10.2 to 33.6)16.0 (5.7 to 22.6)16.1 (10.3 to 21.0)
SecondaryNumber of Participants With Progression-free Survival Events According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase

PFS: Time from randomization until first documentation of PD/death due to any cause, whichever occurred first, regardless of whether participant received subsequent anticancer treatment prior to progression. PD:\>=20% increase in SoD of TLs and an absolute increase of \>= 5 mm of SoD/unequivocal progression of existing NTLs/appearance of new lesion. Participants who had no documented progression and were still alive at the time of analysis were censored at time of latest date of assessment from their last evaluable RECIST v1.1 assessment. PFS is assessed by CD73 expression level either low/high at baseline using Kaplan-Meier method. CD73 low: No CD73 expression in tumor cells/\<50% of tumor cells with 2+/3+ intensity. CD73 high: CD73 expression with 2+/3+ intensity in \>=50% of tumor cells. Number of participants with PFS events is reported.

Time frame:
Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)
Reported as:
Number · Participants with event
Number of Participants With Progression-free Survival Events According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase
Participants with eventGemcitabine + Nab-paclitaxel: CD73 Level = HighOleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = HighOleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = HighGemcitabine + Nab-paclitaxel: CD73 Level = LowOleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = LowOleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = Low
Number of Participants With Progression-free Survival Events According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase3523398912
Statistical analysis
  • Gemcitabine + Nab-paclitaxel: CD73 Level = High vs Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = High · Hazard ratio (hr): 1.004 · 95% CI 0.584 to 1.693Hazard ratio for comparison between treatment groups obtained from Cox Proportional Hazards model with ties handled by the Efron method.
  • Gemcitabine + Nab-paclitaxel: CD73 Level = High vs Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = High · Hazard ratio (hr): 0.598 · 95% CI 0.366 to 0.973Hazard ratio for comparison between treatment groups obtained from Cox Proportional Hazards model with ties handled by the Efron method.
  • Gemcitabine + Nab-paclitaxel: CD73 Level = Low vs Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = Low · Hazard ratio (hr): 1.933 · 95% CI 0.716 to 5.437Hazard ratio for comparison between treatment groups obtained from Cox Proportional Hazards model with ties handled by the Efron method.
  • Gemcitabine + Nab-paclitaxel: CD73 Level = Low vs Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = Low · Hazard ratio (hr): 1.374 · 95% CI 0.550 to 3.707Hazard ratio for comparison between treatment groups obtained from Cox Proportional Hazards model with ties handled by the Efron method.
SecondaryProgression-free Survival According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase

The PFS is defined as the time from randomization until the first documentation of a PD or death due to any cause, whichever occurred first, regardless of whether the participant receives subsequent anticancer treatment prior to progression. The PD is defined as at least a 20% increase in SoD of TLs, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of SoD, or unequivocal progression of existing NTLs, or the appearance of new lesion/s. Participants who had no documented progression and were still alive at time of analysis were censored at time of latest date of assessment from their last evaluable RECIST v1.1 assessment. PFS is assessed by CD73 expression level either low/high at baseline using Kaplan-Meier method. CD73 low: No CD73 expression in tumor cells/\<50% of tumor cells with 2+/3+ intensity. CD73 high: CD73 expression with 2+/3+ intensity in \>=50% of tumor cells.

Time frame:
Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)
Reported as:
Median · Months
Progression-free Survival According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase
MonthsGemcitabine + Nab-paclitaxel: CD73 Level = HighOleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = HighOleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = HighGemcitabine + Nab-paclitaxel: CD73 Level = LowOleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = LowOleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = Low
Progression-free Survival According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase5.6 (3.7 to 7.4)5.2 (1.9 to 6.3)5.5 (4.4 to 9.3)10.5 (6.9 to NA)7.6 (3.3 to 11.2)10.9 (5.7 to 13.2)
SecondaryNumber of Participants With Positive Anti-drug Antibodies (ADA) to Oleclumab

Number of participants with positive ADA to oleclumab are reported. Persistent positive is defined as positive at \>= 2 post-baseline assessments (with \>=16 weeks between first and last positive) or positive at last post-baseline assessment. Transient positive is defined as negative at last post-baseline assessment and positive at only one post-baseline assessment or at \>= 2 post-baseline assessments (with \<16 weeks between first and last positive). Treatment-boosted ADA is defined as baseline ADA positive titer that was boosted to a 4-fold or higher level following drug administration.

Time frame:
Day 1 through 172.1 weeks (Pre-dose on Cycle [C] 1 Day [D] 1, C2D1, C3D1, Day 1 of every 3 cycles starting with C5, through 12 weeks post last dose of oleclumab)
Reported as:
Count of participants · Participants
Number of Participants With Positive Anti-drug Antibodies (ADA) to Oleclumab
ParticipantsDose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOXDose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOXDose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel
ADA positive at baseline000000
ADA positive post-baseline100110
Persistent Positive100100
Transient Positive000010
Treatment-boosted ADA000000
SecondaryNumber of Participants With Positive ADA to Durvalumab

Number of participants with positive ADA to durvalumab are reported. Persistent positive is defined as positive at \>= 2 post-baseline assessments (with \>=16 weeks between first and last positive) or positive at last post-baseline assessment. Transient positive is defined as negative at last post-baseline assessment and positive at only one post-baseline assessment or at \>= 2 post-baseline assessments (with \<16 weeks between first and last positive). Treatment-boosted ADA is defined as baseline ADA positive titer that was boosted to a 4-fold or higher level following drug administration.

Time frame:
Day 1 through 128 weeks (Pre-dose on C1D1, C2D1, C3D1, Day 1 of every 3 cycles starting with C5, through 12 weeks post last dose of durvalumab)
Reported as:
Count of participants · Participants
Number of Participants With Positive ADA to Durvalumab
ParticipantsDose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOXDose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOXDose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel
ADA positive at baseline00002
ADA positive post-baseline10020
Persistent Positive10020
Transient Positive00000
Treatment-boosted ADA00000
SecondarySerum Concentrations of Oleclumab

Serum concentrations of oleclumab are reported.

Time frame:
Ten minutes (mins) (± 5 mins) post end of infusion (EOI), approximately 1 hour (+ 15 mins) after start of infusion on C1D1, C3D1, and C5D1; and pre-dose on C3D1 and C5D1
Reported as:
Geometric mean · μg/mL
Serum Concentrations of Oleclumab
μg/mLDose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOXDose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOXDose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel
C1D1 (EOI)297.6 ± 25.70710.2 ± 21.42412.7 ± 11.12734.6 ± 41.01704.4 ± 30.28725.9 ± 34.69
C3D1 (pre-dose)128.6 ± 10.00211.5 ± 73.40134.3 ± 141.5368.9 ± 2.461164.8 ± 324.1226.8 ± 70.41
C3D1 (EOI)NA ± NA870.3 ± 21.86571.1 ± 15.751181 ± 24.97893.0 ± 30.66894.4 ± 39.22
C5D1 (pre-dose)NA ± NA73.19 ± 130.2—235.7 ± 27.6885.99 ± 192.0116.4 ± 54.0
C5D1 (EOI)NA ± NA948.3 ± 44.90—1057 ± 14.88852.8 ± 24.77753.2 ± 41.32
SecondarySerum Concentrations of Durvalumab

Serum concentrations of durvalumab are reported.

Time frame:
Ten mins (± 5 mins) post EOI, approximately 1 hour (+ 15 mins) after start of infusion on C1D1 and C5D1; and pre-dose on C2D1 and C5D1
Reported as:
Geometric mean · μg/mL
Serum Concentrations of Durvalumab
μg/mLDose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOXDose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOXDose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel
C1D1 (EOI)292.5 ± 11.72374.5 ± 27.50309.0 ± 11.58380.7 ± 56.89345.8 ± 324.2
C2D1 (pre-dose)35.97 ± 51.4414.39 ± 512950.52 ± 57.3059.97 ± 176.786.20 ± 97.95
C5D1 (pre-dose)NA ± NA74.52 ± 28.32—175.9 ± 43.50137.9 ± 48.85
C5D1 (EOI)NA ± NA522.1 ± 46.72—664.5 ± 28.14597.9 ± 23.40
SecondaryPlasma Concentrations of Gemcitabine and Metabolite 2',2'-Difluorodeoxyuridine (dFdU)

Plasma concentrations of gemcitabine and metabolite dFdU are reported.

Time frame:
Ten mins (± 5 mins) post EOI, approximately 30-40 mins after start of infusion on C1D1 and C4D1; and pre-dose on C4D1
Reported as:
Geometric mean · ng/mL
Plasma Concentrations of Gemcitabine and Metabolite 2',2'-Difluorodeoxyuridine (dFdU)
ng/mLDose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-expansion, Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel
Gemcitabine C1D1 (EOI)3194 ± 64.744659 ± 67.413301 ± 192.03315 ± 135.44086 ± 148.9
Gemcitabine C4D1 (pre-dose)NA ± NANA ± NANA ± NANA ± NANA ± NA
Gemcitabine C4D1 (EOI)NA ± NA3530 ± 48.111748 ± 236.51431 ± 446.32998 ± 151.3
dFdU C1D1 (EOI)33700 ± 14.7032160 ± 17.6729510 ± 113.432350 ± 17.1026300 ± 163.9
dFdU C4D1 (pre-dose)NA ± NA434.6 ± 344.7245.1 ± 361.5149.9 ± 147.0177.5 ± 170.0
dFdU C4D1 (EOI)NA ± NA34550 ± 35.3723900 ± 189.121970 ± 130.327260 ± 43.07
SecondaryPlasma Concentrations of Nab-paclitaxel

Plasma concentrations of nab-paclitaxel are reported.

Time frame:
Ten mins (± 5 mins) post EOI, approximately 30-40 mins after start of infusion on C1D1 and C4D1; and pre-dose on C4D1
Reported as:
Geometric mean · ng/mL
Plasma Concentrations of Nab-paclitaxel
ng/mLDose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-expansion, Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel
C1D1 (EOI)1711 ± 80.372685 ± 63.552381 ± 105.22711 ± 81.672611 ± 142.0
C4D1 (pre-dose)NA ± NANA ± NANA ± NANA ± NANA ± NA
C4D1 (EOI)NA ± NA1474 ± 96.121825 ± 178.11445 ± 145.81747 ± 99.26

Adverse events

Collected over Day 1 through 172.1 weeks (maximum observed duration). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxel7/7 (100%)4/7 (57.1%)7/7 (100%)
Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel7/7 (100%)6/7 (85.7%)7/7 (100%)
Dose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOX3/3 (100%)0/3 (0%)3/3 (100%)
Dose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX8/8 (100%)4/8 (50%)8/8 (100%)
Dose-expansion, Gemcitabine + Nab-paclitaxel47/62 (75.8%)34/62 (54.8%)60/62 (96.8%)
Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel32/38 (84.2%)24/38 (63.2%)36/38 (94.7%)
Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel53/70 (75.7%)37/70 (52.9%)70/70 (100%)
Most frequent serious events
Showing 10 of 99
Most frequent serious events
EventDose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOXDose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOXDose-expansion, Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel
PyrexiaGeneral disorders0/72/70/30/85/623/388/70
PneumoniaInfections and infestations2/70/70/30/83/622/381/70
Acute kidney injuryRenal and urinary disorders0/72/70/30/80/621/383/70
VomitingGastrointestinal disorders0/72/70/31/85/620/382/70
NauseaGastrointestinal disorders0/70/70/32/84/620/380/70
CellulitisInfections and infestations1/70/70/30/81/622/380/70
Liver abscessInfections and infestations0/71/70/30/80/620/380/70
Atrial fibrillationCardiac disorders0/71/70/30/80/620/380/70
SepsisInfections and infestations0/71/70/30/84/620/383/70
Spontaneous bacterial peritonitisInfections and infestations0/71/70/30/80/620/380/70
Most frequent other events
Showing 10 of 365
Most frequent other events
EventDose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOXDose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOXDose-expansion, Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel
FatigueGeneral disorders6/77/72/36/830/6225/3841/70
NauseaGastrointestinal disorders6/76/72/34/826/6226/3841/70
ConstipationGastrointestinal disorders2/75/72/32/810/6215/3818/70
DiarrhoeaGastrointestinal disorders5/72/71/35/818/6214/3836/70
NeutropeniaBlood and lymphatic system disorders2/72/72/31/822/6214/3816/70
ThrombocytopeniaBlood and lymphatic system disorders2/72/72/31/86/627/3813/70
DysgeusiaNervous system disorders0/73/72/30/810/625/3812/70
Abdominal painGastrointestinal disorders2/72/72/31/812/626/3813/70
Alanine aminotransferase increasedInvestigations3/74/70/32/88/629/3816/70
Decreased appetiteMetabolism and nutrition disorders4/73/71/33/816/6215/3821/70

Baseline characteristics

As-treated population included all participants who received any study drugs and were analyzed according to the treatment they actually received.

Age, Continuous
Age, Continuous(Years)Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOXDose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOXDose-expansion, Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxelTotal
Mean66.7 ± 12.859.6 ± 11.467.0 ± 14.964.8 ± 4.865.6 ± 8.062.5 ± 11.162.9 ± 8.363.8 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOXDose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOXDose-expansion, Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxelTotal
Female341426173489
Male4324362136106
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOXDose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOXDose-expansion, Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxelTotal
Hispanic or Latino00010113
Not Hispanic or Latino7737613769191
Unknown or Not Reported00001001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxelDose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOXDose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOXDose-expansion, Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxelDose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxelTotal
American Indian or Alaska Native00000011
Asian00005117
Native Hawaiian or Other Pacific Islander10000001
Black or African American010232210
White6536543364171
More than one race01000102
Unknown or Not Reported00000123
08

Study locations

27 sites
  • Research Site
    La Jolla, California 92093, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    Fort Myers, Florida 33901, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Boston, Massachusetts 02114, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    Ann Arbor, Michigan 48109, United States
  • Research Site
    Buffalo, New York 14263, United States
  • Research Site
    Durham, North Carolina 27710, United States
  • Research Site
    Cincinnati, Ohio 45219, United States
  • Research Site
    Columbus, Ohio 43210, United States
  • Research Site
    Philadelphia, Pennsylvania 19111, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Dallas, Texas 75235, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Charlottesville, Virginia 22908, United States
  • Research Site
    Seattle, Washington 98109, United States
  • Research Site
    Madison, Wisconsin 53705, United States
  • Research Site
    Blacktown, 2148, Australia
  • Research Site
    Clayton, 3168, Australia
  • Research Site
    Heidelberg, 3084, Australia
  • Research Site
    St Leonards, 2065, Australia
  • Research Site
    Oslo, N-0379, Norway
  • Research Site
    Barcelona, 08035, Spain
  • Research Site
    Fuenlabrada, 28942, Spain
  • Research Site
    Oviedo, 33011, Spain
  • Research Site
    Pamplona, 31008, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Jul 2022, 49 months.

Results were first posted in Oct 2023, 1 year 2 months after primary completion.

Of 40 phase 1/2 interventional studies under Carcinoma, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 93. This study's 49 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2018
First posted
Aug 2, 2018
StartActual
Jun 21, 2018
Primary completionActual
Jul 22, 2022
CompletionActual
Jul 22, 2022
Results first posted
Oct 3, 2023
Last update
Oct 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03611556
Lead sponsor
MedImmune LLC
Responsible party
Sponsor
First posted
Aug 2, 2018
Start date
Jun 21, 2018
Primary completion
Jul 22, 2022
Completion
Jul 22, 2022
Results posted
Oct 3, 2023
Last update
Oct 3, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Oleclumab · Gemcitabine · Albumin-Bound Paclitaxel

Start the discussion